10 results on '"Frederic Davi"'
Search Results
2. Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience
- Author
-
Anne Sophie Alary, Carole Maute, Olivier Kosmider, Pierre Sujobert, Audrey Gauthier, Elizabeth Macintyre, Claude Preudhomme, Sandrine Hayette, Damien Luque-Paz, Fanny Baran-Marszak, Frederic Davi, Eric Lippert, Pascale Cornillet-Lefebvre, Marie Helene Delfau-Larue, Bruno Cassinat, Jean Michel Cayuela, and Pascale Flandrin-Gresta
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Molecular tests have become an indispensable tool for the diagnosis and prognosis of hematological malignancies and are subject to accreditation according to the International Standard ISO 15189. National standardization of these techniques is essential to ensure that patients throughout France benefit from the same care. We report here on the experience of the GBMHM (Groupe des Biologistes Moléculaires des Hémopathies Malignes). By organizing External Evaluation of Quality (EEQ) programs and training meetings, the GBMHM has contributed to improvement and standardization of molecular tests in 64 French laboratories. A retrospective analysis of the quality-control results of 11 national campaigns spanning 10 years was performed for the 3 most frequently prescribed tests: BCR-ABL1, JAK2 V617F, and lymphoid clonality. For each test, particular attention was placed on comparing methodologies and their evolution throughout the period. The establishment of the BCR-ABL1, JAK2 V617F, and lymphoid clonality EEQ programs and the associated training meetings have initiated a process of collective standardization concerning the methods of implementation (JAK2 V617F) and the interpretation and formulation of results (lymphoid clonality). In addition, it resulted in objective improvement in technical performance (BCR-ABL1). Our evaluation of the impact of these EEQ programs demonstrates that it is possible to obtain reproducible values across different laboratories in France by applying national recommendations. To our knowledge, this is the first publication that evaluates the impact of a national quality assurance program on improving molecular results in hematology.
- Published
- 2021
- Full Text
- View/download PDF
3. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonality: A Comparative Study from the EuroClonality Consortium
- Author
-
Marine Armand, Coralie Derrieux, Kheira Beldjord, Tamara Wabeke, Dido Lenze, Elke Boone, Monika Bruggemann, Paul A.S. Evans, Paula Gameiro, Michael Hummel, Patrick Villarese, Patricia J.T.A. Groenen, Anton W. Langerak, Elizabeth A. Macintyre, and Frederic Davi
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract. T-cell Receptor Gamma (TRG) rearrangements are commonly used to detect clonal lymphoproliferations in hematopathology, since they are rearranged in virtually all T lymphocytes and have a relatively limited recombinatorial repertoire, which reduces the risk of false negative results, at the cost of potential false positivity. We developed an initial one-tube, 2-fluorochrome EuroClonality TRG PCR multiplex (TRG-1T-2F) which was compared to the original 2-tube, 2-fluorochrome EuroClonality/BIOMED-2 TRG PCR (TRG-2T-2F) and a commercial Invivoscribe one-tube, one-fluorochrome kit (IVS-1T-1F) on a series of 239 samples, including both T-cell malignancies and reactive cases. This initial assay yielded discrepant results between the 10 participating EuroClonality laboratories when using 2 fluorochromes, leading to adoption of a final single color EuroClonality strategy (TRG-1T-1F). Compared to TRG-2T-2F, both TRG-1T-1F and IVS-1T-1F demonstrated easier interpretation and a lower risk of false positive from minor peaks in dispersed repertoires. Both generate smaller fragments and as such are likely to be better adapted to analysis of formalin-fixed paraffin-embedded (FFPE) tissue samples. Their differential performance was mainly explained by (i) superposition of biallelic rearrangements with IVS-1T-1F, due to more extensive overlapping of the repertoires and (ii) intentional omission of the TRGJP primer in TRG-1T-1F, in order to avoid the potential risk of confusion of consensus TRG V9-JP normal rearrangements with a pathological clone.
- Published
- 2019
- Full Text
- View/download PDF
4. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonality: A Comparative Study from the EuroClonality Consortium
- Author
-
Monika Brüggemann, Paula Gameiro, Marine Armand, Patrick Villarese, Patricia J. T. A. Groenen, Michael Hummel, Coralie Derrieux, Tamara Wabeke, Elizabeth Macintyre, Elke Boone, Paul Evans, Anton W. Langerak, Kheira Beldjord, Frederic Davi, Dido Lenze, and Immunology
- Subjects
clone (Java method) ,medicine.medical_specialty ,Potential risk ,lcsh:RC633-647.5 ,T cell ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,Biology ,False positivity ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,Molecular biology ,Article ,medicine.anatomical_structure ,All institutes and research themes of the Radboud University Medical Center ,Multiplex polymerase chain reaction ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,medicine ,Multiplex ,Primer (molecular biology) ,Hematopathology - Abstract
Supplemental Digital Content is available in the text, T-cell Receptor Gamma (TRG) rearrangements are commonly used to detect clonal lymphoproliferations in hematopathology, since they are rearranged in virtually all T lymphocytes and have a relatively limited recombinatorial repertoire, which reduces the risk of false negative results, at the cost of potential false positivity. We developed an initial one-tube, 2-fluorochrome EuroClonality TRG PCR multiplex (TRG-1T-2F) which was compared to the original 2-tube, 2-fluorochrome EuroClonality/BIOMED-2 TRG PCR (TRG-2T-2F) and a commercial Invivoscribe one-tube, one-fluorochrome kit (IVS-1T-1F) on a series of 239 samples, including both T-cell malignancies and reactive cases. This initial assay yielded discrepant results between the 10 participating EuroClonality laboratories when using 2 fluorochromes, leading to adoption of a final single color EuroClonality strategy (TRG-1T-1F). Compared to TRG-2T-2F, both TRG-1T-1F and IVS-1T-1F demonstrated easier interpretation and a lower risk of false positive from minor peaks in dispersed repertoires. Both generate smaller fragments and as such are likely to be better adapted to analysis of formalin-fixed paraffin-embedded (FFPE) tissue samples. Their differential performance was mainly explained by (i) superposition of biallelic rearrangements with IVS-1T-1F, due to more extensive overlapping of the repertoires and (ii) intentional omission of the TRGJP primer in TRG-1T-1F, in order to avoid the potential risk of confusion of consensus TRG V9-JP normal rearrangements with a pathological clone.
- Published
- 2019
5. The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies
- Author
-
Gilles Salles, Catherine Thieblemont, Vahid Asnafi, Yannick Le Bris, Elizabeth Macintyre, Audrey Gros, Pierre Sujobert, David Sibon, Sarah Huet, Cedric Pastoret, Jean-Philippe Merlio, Clémentine Sarkozy, Fabrice Jardin, Laurence de Leval, Claude Preudhomme, Frederic Davi, Philippe Gaulard, Mary Callanan, Jonchère, Laurent, Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Division de cardiologie [CHU Vaudois] (CHUV), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Paris Diderot - Paris 7 (UPD7), Université Paris Descartes - Paris 5 (UPD5), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, CHU Henri Mondor, Université Paris-Est Marne-la-Vallée (UPEM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor [Créteil], Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille
- Subjects
0303 health sciences ,lcsh:RC633-647.5 ,business.industry ,MEDLINE ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,lcsh:Diseases of the blood and blood-forming organs ,Computational biology ,Hematology ,DNA sequencing ,03 medical and health sciences ,Text mining ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,030220 oncology & carcinogenesis ,Perspective ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Medicine ,business ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,030215 immunology - Abstract
International audience; Supplemental Digital Content is available in the text.
- Published
- 2018
6. PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS
- Author
-
Frederic Davi, Caroline Algrin, Clementine Gabillaud, Nathalie Nadal, Philippe Dessen, Baptiste Gaillard, L. Baseggio, Sandra Fert-Ferrer, K. Diop, Isabelle Radford-Weiss, Marc Muller, Nathalie Auger, Benoit Quilichini, M Le Garff-Tavernier, Virginie Eclache, Evelyne Callet-Bauchu, Christine Lefebvre, Elodie Pramil, Nathalie Droin, Olivier Bernard, Damien Roos-Weil, Elise Chapiro, Stéphanie Struski, Florence Nguyen-Khac, Antoine Ittel, Catherine Settegrana, Marie-Agnès Collonge-Rame, Karim Maloum, Santos A. Susin, and Veronique Leblond
- Subjects
B-cell prolymphocytic leukemia ,medicine ,Cancer research ,Mantle cell lymphoma ,Hematology ,Biology ,medicine.disease - Published
- 2019
7. Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
- Author
-
Meryl Darlington, Pierre Sujobert, Olivier Kosmider, Damien Luque Paz, Sophie Kaltenbach, Martin Figeac, Sandrine Hayette, Nadia Mezaour, Séverine Coquerelle, Anne-Sophie Alary, Audrey Bidet, Yannick Le Bris, Eric Delabesse, Frédéric Davi, Claude Preudhomme, Isabelle Durand-Zaleski, Elizabeth Macintyre, Mélissa Alame, Fanny Baran-Marzak, Marc G. Berger, Dominique Bories, Aurélie Caye-Eude, Jean-Michel Cayuela, Pascale Cornillet-Lefebvre, François Delhommeau, Marie-Hélène Estienne-Felix, Pascaline Etancelin, Pascale Flandrin-Gresta, Eric Lippert, Christophe Marzac, Laurent Miguet, Cédric Pastoret, Sophie Raynaud, and David Rizzo
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all or only significant targets). Impact was defined by the identification of (1) an actionable mutation, (2) a mutation with prognostic and/or theranostic value, and/or (3) a mutation allowing nosological refinement, reported by local investigators. A microcosting study was undertaken in 4 laboratories, identifying the types and volumes of resources required for each procedural step. Individual index prescriptions for 3961 patients were available for impact analysis on the management of myeloid disorders (two thirds) and, mainly mature B, lymphoid disorders (one third). NGS results were considered to impact the management for 73.4% of prescriptions: useful for evaluation of prognostic risk in 34.9% and necessary for treatment adaptation (actionable) in 19.6%, but having no immediate individual therapeutic impact in 18.9%. The average overall cost per sample was 191 € for the restricted mature lymphoid amplicon panel. Capture panel costs varied from 369 € to 513 €. Unit costs varied from 0.5 € to 5.7 € per kb sequenced, from 3.6 € to 11.3 € per target gene/hot-spot sequenced and from 4.3 € to 73.8 € per target gene/hot-spot reported. Comparable costs for the Amplicon panels were 5–8 € per kb and 10.5–14.7 € per target gene/hot-spot sequenced and reported, demonstrating comparable costs with greater informativity/flexibility for capture strategies. Sustainable funding of precision medicine requires a transparent discussion of its impact on care pathways and its financial aspects.
- Published
- 2023
- Full Text
- View/download PDF
8. Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy
- Author
-
Kamel Laribi, Alix Baugier de Materre, David Ghez, Caroline Dartigeas, Cécile Tomowiak, Béatrice Mahé, Jean-Baptiste Micol, Fatiha Merabet, Stéphane Leprêtre, Charles Herbaux, Loïc Ysebaert, Ronan Le Calloch, Lise Willems, Maud Voldoire, Damien Roos-Weil, Clotilde Bravetti, Yamina Touileb, Frédéric Davi, Florence Nguyen-Khac, Karim Maloum, and Marie C. Béné
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
9. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
- Author
-
Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, Florence Cymbalista, Caroline Dartigeas, Frédéric Davi, Sophie de Guibert, Alain Delmer, Marie-Sarah Dilhuydy, Pierre Feugier, Luc-Matthieu Fornecker, David Ghez, Romain Guieze, Kamel Laribi, Véronique Leblond, Stéphane Leprêtre, Rémi Letestu, Vincent Lévy, Florence Nguyen-Khac, Anne-Sophie Michallet, Cécile Tomowiak, Olivier Tournilhac, Loïc Ysebaert, Xavier Troussard, and on the behalf of the FILO-LLC Group
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract. As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.
- Published
- 2020
- Full Text
- View/download PDF
10. The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies
- Author
-
Pierre Sujobert, Yannick Le Bris, Laurence de Leval, Audrey Gros, Jean Philippe Merlio, Cedric Pastoret, Sarah Huet, Clémentine Sarkozy, Frédéric Davi, Mary Callanan, Catherine Thieblemont, David Sibon, Vahid Asnafi, Claude Preudhomme, Philippe Gaulard, Fabrice Jardin, Gilles Salles, and Elizabeth Macintyre
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.